NI-2901 / LightChain Bioscience - LARVOL DELTA

NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade (AACR 2023) - "PD-L1-independent CD47 antitumor activity was assessed in vivo in a PD-L1-negative xenograft model and compared to the anti-CD47 magrolimab analog...As a result, the bsAb is able to enhance the phagocytosis of PD-L1-negative and -positive tumor cell lines induced by mAbs targeting tumor-associated antigens (e.g. rituximab, trastuzumab and anti-CD19) and demonstrates in vivo activity in the Raji B-cell lymphoma xenograft model. Given its high affinity for PD-L1, NI-2901 triggers an effective blockade of the PD-1/PD-L1 interaction, inducing T-cell activation in vitro to a degree similar to anti-PD-L1 benchmark antibodies atezolizumab and avelumab...Also, NI-2901 demonstrated significant antitumor activity in vivo and is therefore expected to show improved clinical efficacy over PD-1/PD-L1 blockade alone. The bsAb was well-tolerated in NHP without inducing RBC or platelet depletion."

Checkpoint block • Checkpoint inhibition • IO biomarker • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD47 • SIRPA

An affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade (SITC 2022) - "PD-L1-independent CD47 antitumor activity was assessed in vivo in a PD-L1-negative xenograft model and compared to the humanized IgG4 anti-CD47 antibody, magrolimab...Given its high affinity for PD-L1, NI-2901 triggers effective blockade of the PD-1/PD-L1 interaction on cells, inducing T-cell activation in vitro similar to the anti-PD-L1 antibodies, atezolizumab and avelumab...Conclusions As a dual immune checkpoint inhibitor, NI-2901 triggers effective T-cell activation, enhances phagocytosis of tumor cells and is expected to have improved efficacy over PD-1/PD-L1 blockade alone. The bsAb is well-tolerated in NHP at predicted therapeutic doses without inducing RBC or platelet depletion."

Checkpoint inhibition • IO biomarker • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20 • CD47 • HER-2 • SIRPA

NI-2901, a CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade with fine-tuned affinity to reduce erythrocyte binding and improve biodistribution (AACR 2022) - "The candidate molecules were screened for binding and receptor-blocking activity and tested for their capacity to enhance T-cell activation and phagocytosis of tumor cells in the presence of anti-HER-2 mAb, trastuzumab...The CD47xPD-L1 bsAbs demonstrated an effective blockade of the PD-1/PD-L1 interaction, being able to induce T-cell activation in vitro similar to the anti-PD-L1 clinical benchmark, atezolizumab...Selected bsAbs will be now tested for tolerability and pharmacokinetic profiles in human-CD47/human-SIRPα transgenic mice. Lead candidate(s) will be evaluated further for PK and safety attributes in non-human primates in early Q1, 2022."

Checkpoint inhibition • Oncology • CD47 • SIRPA

"#LightChainBioscience reported at #AACR22 #NI2601 & #NI2901 #CD47xPDL1 #BispecificAntibodies https://t.co/WppsKybJ9X" (,@1stOncology)

Oncology

"#LightChainBioscience to present at #SITC21 #NI2601 & #NI2901 #BispecificAntibody programs https://t.co/5aM6onnzv5" (,@1stOncology)

Oncology